Search

Your search keyword '"Reuben, James M."' showing total 762 results
Start Over Author "Reuben, James M."
762 results on '"Reuben, James M."'

4. Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy

Author

Iwase, Toshiaki, primary, Cohen, Evan N., additional, Gao, Hui, additional, Alexander, Angela, additional, Kai, Megumi, additional, Chiv, Vivian, additional, Wang, Xiaoping, additional, Krishnamurthy, Savitri, additional, Liu, Diane, additional, Shen, Yu, additional, Kida, Kumiko, additional, Reuben, Alexandre, additional, Layman, Rachel, additional, Ramirez, David, additional, Tripathy, Debu, additional, Moulder, Stacy L., additional, Yam, Clinton, additional, Valero, Vicente, additional, Lim, Bora, additional, Reuben, James M., additional, and Ueno, Naoto T., additional

Published
2024
Full Text
View/download PDF

5. Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression

Author

Park, Jihyun, Tacam, Moises J., Chauhan, Gaurav, Cohen, Evan N., Gagliardi, Maria, Iles, Lakesla R., Ueno, Naoto T., Battula, Venkata L., Sohn, Yoo-Kyoung, Wang, Xiaoping, Kim, Hak-Sung, Krishnamurthy, Savitri, Fowlkes, Natalie W., Green, Morgan M., Bartholomeusz, Geoffrey A., Tripathy, Debu, Reuben, James M., and Bartholomeusz, Chandra

Published
2021
Full Text
View/download PDF

6. Establishment and Characterization of a New Cell Line of Canine Inflammatory Mammary Cancer: IPC-366

Author

Cáceres Ramos, Sara Cristina, Peña Fernández, Laura Luisa, Andrés Gamazo, Paloma Jimena De, Illera Del Portal, Josefina María, Lopez, Mirtha S., Woodward, Wendy A., Reuben, James M., Illera Del Portal, Juan Carlos, Cáceres Ramos, Sara Cristina, Peña Fernández, Laura Luisa, Andrés Gamazo, Paloma Jimena De, Illera Del Portal, Josefina María, Lopez, Mirtha S., Woodward, Wendy A., Reuben, James M., and Illera Del Portal, Juan Carlos

Abstract

Canine inflammatory mammary cancer (IMC) shares epidemiologic, histopathological and clinical characteristics with the disease in humans and has been proposed as a natural model for human inflammatory breast cancer (IBC). The aim of this study was to characterize a new cell line from IMC (IPC-366) for the comparative study of both IMC and IBC. Tumors cells from a female dog with clinical IMC were collected. The cells were grown under adherent conditions. The growth, cytological, ultrastructural and immunohistochemical (IHC) characteristics of IPC-366 were evaluated. Ten female Balb/SCID mice were inoculated with IPC-366 cells to assess their tumorigenicity and metastatic potential. Chromosome aberration test and Karyotype revealed the presence of structural aberration, numerical and neutral rearrangements, demonstrating a chromosomal instability. Microscopic examination of tumor revealed an epithelial morphology with marked anysocytosis. Cytological and histological examination of smears and ultrathin sections by electron microscopy revealed that IPC-366 is formed by highly malignant large round or polygonal cells characterized by marked atypia and prominent nucleoli and frequent multinucleated cells. Some cells had cytoplasmic empty spaces covered by cytoplasmic membrane resembling capillary endothelial cells, a phenomenon that has been related to s vasculogenic mimicry. IHC characterization of IPC-366 was basal-like: epithelial cells (AE1/AE3+, CK14+, vimentin+, actin-, p63-, ER-, PR-, HER-2, E-cadherin, overexpressed COX-2 and high Ki-67 proliferation index (87.15 %). At 2 weeks after inoculating the IPC-366 cells, a tumor mass was found in 100 % of mice. At 4 weeks metastases in lung and lymph nodes were found. Xenograph tumors maintained the original IHC characteristics of the female dog tumor. In summary, the cell line IPC-366 is a fast growing malignant triple negative cell line model of inflammatory mammary carcinoma that can be used for the comparative stud, Spanish Ministry of Science and Education SAF 2009-10572, Depto. de Fisiología, Fac. de Veterinaria, TRUE, pub

Published
2024

7. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Author

Vitale, Candida, Falchi, Lorenzo, Hacken, Elisa ten, Gao, Hui, Shaim, Hila, Van Roosbroeck, Katrien, Calin, George, O'Brien, Susan, Faderl, Stefan, Wang, Xuemei, Wierda, William G, Rezvani, Katayoun, Reuben, James M, Burger, Jan A, Keating, Michael J, and Ferrajoli, Alessandra

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Emerging Infectious Diseases, Cancer, Infectious Diseases, Hematology, Clinical Research, Rare Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Disease-Free Survival, Female, Humans, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Recurrence, Local, Thalidomide, Treatment Outcome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeWe evaluated efficacy and tolerability of the combination of ofatumumab and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), and explored whether immune system characteristics could influence the response to treatment.Experimental designThirty-four patients were enrolled in this phase II study. Ofatumumab was administered at a dose of 300 mg on day 1, 1,000 mg on days 8, 15, and 22 during course 1, 1,000 mg on day 1 during courses 3-6, and once every other course during courses 7-24 (28-day courses). Oral lenalidomide (10 mg daily) was started on day 9 and continued for as long as a clinical benefit was observed.ResultsThe overall response rate was 71%. Eight patients (24%) achieved a complete remission (CR) or CR with incomplete recovery of blood counts, including 9% with minimal residual disease-negative CR. The median progression-free survival was 16 months, and the estimated 5-year survival was 53%. The most common treatment-related toxicity was neutropenia (grade >2 in 18% of the 574 patient courses). The most frequent infectious complications were pneumonia and neutropenic fever (24% and 9% of patients, respectively). We observed that patients who achieved a CR had at baseline higher numbers and a better preserved function of T cells and natural killer cells compared with non-responders.ConclusionsThe combination of ofatumumab and lenalidomide is a well-tolerated regimen that induces durable responses in the majority of patients with relapsed/refractory CLL. Our correlative data suggest a role of competent immune system in supporting the efficacy of this treatment. Clin Cancer Res; 22(10); 2359-67. ©2016 AACR.

Published
2016

14. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.

Author

Naing, Aung, Reuben, James M, Camacho, Luis H, Gao, Hui, Lee, Bang-Ning, Cohen, Evan N, Verschraegen, Claire, Stephen, Saneese, Aaron, Joann, Hong, David, Wheler, Jennifer, and Kurzrock, Razelle

Subjects
cancer, immunity, interferon alpha, phase 1, sodium stibogluconate, Oncology and Carcinogenesis
Abstract

PurposeSodium stibogluconate (SSG), a small molecule inhibitor of protein tyrosine phosphatases, combined with IFN-alpha-2b (IFN-α) inhibited solid tumor cell line growth in vitro. We conducted a phase I clinical trial with SSG plus IFN-α in advanced cancer patients to assess tolerance, maximum tolerated dose (MTD) and immune system effects.Experimental designSSG was administered intravenously alone for five days of week 1, cycle 1 (21 days per cycle) and together with IFN-α 2b s (3 million units sc TIW) in week 2, and after a rest during week 3, on a 2-week on/1-week off cycle. SSG dose levels were 400, 600, 900, 1125, and 1350 mg/m(2).ResultsTwenty-four patients were studied. Common toxicities included asymptomatic elevated serum lipase, thrombocytopenia, fatigue, fever, chills and anemia. The dose-limiting toxicities (DLT) were hypokalemia, thrombocytopenia, fatigue, pancreatitis and skin rash. The MTD was 900 mg/m(2 )SSG and IFN-α, 3 million units TIW. At this dose, patients had a significantly lower number of regulatory T cells (T(R )Cells) (p = 0.012), myeloid dendritic cells (mDC) (p = 0.028); higher percentage of natural killer (NK) cells that synthesized perforin (p = 0.046) and of plasmacytoid dendritic cells (pDC) that secreted IFN-α (p = 0.018) in response to activation through toll-like receptor (TLR) 7 and TLR 8 by CL097, the highly water-soluble derivative of the imidazoquinoline compound R848.ConclusionsSSG in combination with IFN-α 2b was well tolerated and augmented cellular immune parameters.

Published
2011

22. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancer

Author

Lee, Jangsoon, primary, Kida, Kumiko, additional, Liu, Huey, additional, Manyam, Ganiraju C., additional, Gi, Young Jin, additional, Multani, Asha S., additional, Wang, Jing, additional, Jayachandran, Gitanjali, additional, Reuben, James M., additional, Huo, Lei, additional, Tripathy, Debu, additional, and Ueno, Naoto T., additional

Published
2023
Full Text
View/download PDF

23. Abstract 3635: TBK1 inhibition potentiates the efficacy of AXL-targeted therapy by modulating tumor microenvironment in aggressive breast cancers

Author

Phi, Lan, primary, Semba, Takashi, additional, Trinh, Ngu V., additional, Zou, Fang, additional, Foulks, Jason M., additional, Warner, Steven L., additional, Krishnamurthy, Savitri, additional, Long, James P., additional, Reuben, James M., additional, Tripathy, Debu, additional, Ueno, Naoto T., additional, and Wang, Xiaoping, additional

Published
2023
Full Text
View/download PDF

24. Data from Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

Author

Reddy, Sangeetha M., primary, Reuben, Alexandre, primary, Barua, Souptik, primary, Jiang, Hong, primary, Zhang, Shaojun, primary, Wang, Linghua, primary, Gopalakrishnan, Vancheswaran, primary, Hudgens, Courtney W., primary, Tetzlaff, Michael T., primary, Reuben, James M., primary, Tsujikawa, Takahiro, primary, Coussens, Lisa M., primary, Wani, Khalida, primary, He, Yan, primary, Villareal, Lily, primary, Wood, Anita, primary, Rao, Arvind, primary, Woodward, Wendy A., primary, Ueno, Naoto T., primary, Krishnamurthy, Savitri, primary, Wargo, Jennifer A., primary, and Mittendorf, Elizabeth A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table from Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

Author

Reddy, Sangeetha M., primary, Reuben, Alexandre, primary, Barua, Souptik, primary, Jiang, Hong, primary, Zhang, Shaojun, primary, Wang, Linghua, primary, Gopalakrishnan, Vancheswaran, primary, Hudgens, Courtney W., primary, Tetzlaff, Michael T., primary, Reuben, James M., primary, Tsujikawa, Takahiro, primary, Coussens, Lisa M., primary, Wani, Khalida, primary, He, Yan, primary, Villareal, Lily, primary, Wood, Anita, primary, Rao, Arvind, primary, Woodward, Wendy A., primary, Ueno, Naoto T., primary, Krishnamurthy, Savitri, primary, Wargo, Jennifer A., primary, and Mittendorf, Elizabeth A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures from Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer

Author

Reddy, Sangeetha M., primary, Reuben, Alexandre, primary, Barua, Souptik, primary, Jiang, Hong, primary, Zhang, Shaojun, primary, Wang, Linghua, primary, Gopalakrishnan, Vancheswaran, primary, Hudgens, Courtney W., primary, Tetzlaff, Michael T., primary, Reuben, James M., primary, Tsujikawa, Takahiro, primary, Coussens, Lisa M., primary, Wani, Khalida, primary, He, Yan, primary, Villareal, Lily, primary, Wood, Anita, primary, Rao, Arvind, primary, Woodward, Wendy A., primary, Ueno, Naoto T., primary, Krishnamurthy, Savitri, primary, Wargo, Jennifer A., primary, and Mittendorf, Elizabeth A., primary

Published
2023
Full Text
View/download PDF

27. Data from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Author

Giordano, Antonio, primary, Gao, Hui, primary, Anfossi, Simone, primary, Cohen, Evan, primary, Mego, Michal, primary, Lee, Bang-Ning, primary, Tin, Sanda, primary, De Laurentiis, Michele, primary, Parker, Charla A., primary, Alvarez, Ricardo H., primary, Valero, Vicente, primary, Ueno, Naoto T., primary, De Placido, Sabino, primary, Mani, Sendurai A., primary, Esteva, Francisco J., primary, Cristofanilli, Massimo, primary, and Reuben, James M., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table S1 from 4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells

Author

Harao, Michiko, primary, Forget, Marie-Andrée, primary, Roszik, Jason, primary, Gao, Hui, primary, Babiera, Gildy V., primary, Krishnamurthy, Savitri, primary, Chacon, Jessica A., primary, Li, Shumin, primary, Mittendorf, Elizabeth A., primary, DeSnyder, Sarah M., primary, Rockwood, Korrene F., primary, Bernatchez, Chantale, primary, Ueno, Naoto T., primary, Radvanyi, Laszlo G., primary, Vence, Luis, primary, Haymaker, Cara, primary, and Reuben, James M., primary

Published
2023
Full Text
View/download PDF

29. Data from 4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells

Author

Harao, Michiko, primary, Forget, Marie-Andrée, primary, Roszik, Jason, primary, Gao, Hui, primary, Babiera, Gildy V., primary, Krishnamurthy, Savitri, primary, Chacon, Jessica A., primary, Li, Shumin, primary, Mittendorf, Elizabeth A., primary, DeSnyder, Sarah M., primary, Rockwood, Korrene F., primary, Bernatchez, Chantale, primary, Ueno, Naoto T., primary, Radvanyi, Laszlo G., primary, Vence, Luis, primary, Haymaker, Cara, primary, and Reuben, James M., primary

Published
2023
Full Text
View/download PDF

30. Data from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma

Author

Gonzalez-Villasana, Vianey, primary, Rodriguez-Aguayo, Cristian, primary, Arumugam, Thiruvengadam, primary, Cruz-Monserrate, Zobeida, primary, Fuentes-Mattei, Enrique, primary, Deng, Defeng, primary, Hwang, Rosa F., primary, Wang, Huamin, primary, Ivan, Cristina, primary, Garza, Raul Joshua, primary, Cohen, Evan, primary, Gao, Hui, primary, Armaiz-Pena, Guillermo N., primary, del C. Monroig-Bosque, Paloma, primary, Philip, Bincy, primary, Rashed, Mohammed H., primary, Aslan, Burcu, primary, Erdogan, Mumin Alper, primary, Gutierrez-Puente, Yolanda, primary, Ozpolat, Bulent, primary, Reuben, James M., primary, Sood, Anil K., primary, Logsdon, Craig, primary, and Lopez-Berestein, Gabriel, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure Legends, Materials and Methods, and Table 1 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma

Author

Gonzalez-Villasana, Vianey, primary, Rodriguez-Aguayo, Cristian, primary, Arumugam, Thiruvengadam, primary, Cruz-Monserrate, Zobeida, primary, Fuentes-Mattei, Enrique, primary, Deng, Defeng, primary, Hwang, Rosa F., primary, Wang, Huamin, primary, Ivan, Cristina, primary, Garza, Raul Joshua, primary, Cohen, Evan, primary, Gao, Hui, primary, Armaiz-Pena, Guillermo N., primary, del C. Monroig-Bosque, Paloma, primary, Philip, Bincy, primary, Rashed, Mohammed H., primary, Aslan, Burcu, primary, Erdogan, Mumin Alper, primary, Gutierrez-Puente, Yolanda, primary, Ozpolat, Bulent, primary, Reuben, James M., primary, Sood, Anil K., primary, Logsdon, Craig, primary, and Lopez-Berestein, Gabriel, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figures 1-7 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma

Author

Gonzalez-Villasana, Vianey, primary, Rodriguez-Aguayo, Cristian, primary, Arumugam, Thiruvengadam, primary, Cruz-Monserrate, Zobeida, primary, Fuentes-Mattei, Enrique, primary, Deng, Defeng, primary, Hwang, Rosa F., primary, Wang, Huamin, primary, Ivan, Cristina, primary, Garza, Raul Joshua, primary, Cohen, Evan, primary, Gao, Hui, primary, Armaiz-Pena, Guillermo N., primary, del C. Monroig-Bosque, Paloma, primary, Philip, Bincy, primary, Rashed, Mohammed H., primary, Aslan, Burcu, primary, Erdogan, Mumin Alper, primary, Gutierrez-Puente, Yolanda, primary, Ozpolat, Bulent, primary, Reuben, James M., primary, Sood, Anil K., primary, Logsdon, Craig, primary, and Lopez-Berestein, Gabriel, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 1 from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Author

Giordano, Antonio, primary, Gao, Hui, primary, Anfossi, Simone, primary, Cohen, Evan, primary, Mego, Michal, primary, Lee, Bang-Ning, primary, Tin, Sanda, primary, De Laurentiis, Michele, primary, Parker, Charla A., primary, Alvarez, Ricardo H., primary, Valero, Vicente, primary, Ueno, Naoto T., primary, De Placido, Sabino, primary, Mani, Sendurai A., primary, Esteva, Francisco J., primary, Cristofanilli, Massimo, primary, and Reuben, James M., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure Legend from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Author

Giordano, Antonio, primary, Gao, Hui, primary, Anfossi, Simone, primary, Cohen, Evan, primary, Mego, Michal, primary, Lee, Bang-Ning, primary, Tin, Sanda, primary, De Laurentiis, Michele, primary, Parker, Charla A., primary, Alvarez, Ricardo H., primary, Valero, Vicente, primary, Ueno, Naoto T., primary, De Placido, Sabino, primary, Mani, Sendurai A., primary, Esteva, Francisco J., primary, Cristofanilli, Massimo, primary, and Reuben, James M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Tables from Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets

Author

Van Laere, Steven J., primary, Ueno, Naoto T., primary, Finetti, Pascal, primary, Vermeulen, Peter, primary, Lucci, Anthony, primary, Robertson, Fredika M., primary, Marsan, Melike, primary, Iwamoto, Takayuki, primary, Krishnamurthy, Savitri, primary, Masuda, Hiroko, primary, van Dam, Peter, primary, Woodward, Wendy A., primary, Viens, Patrice, primary, Cristofanilli, Massimo, primary, Birnbaum, Daniel, primary, Dirix, Luc, primary, Reuben, James M., primary, and Bertucci, François, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Tables 1,2,3,4 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Author

Vitale, Candida, primary, Falchi, Lorenzo, primary, ten Hacken, Elisa, primary, Gao, Hui, primary, Shaim, Hila, primary, Van Roosbroeck, Katrien, primary, Calin, George, primary, O'Brien, Susan, primary, Faderl, Stefan, primary, Wang, Xuemei, primary, Wierda, William G., primary, Rezvani, Katayoun, primary, Reuben, James M., primary, Burger, Jan A., primary, Keating, Michael J., primary, and Ferrajoli, Alessandra, primary

Published
2023
Full Text
View/download PDF

37. Figures S1-S6 and Tables S1-S2 from Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy

Author

Adams, Daniel L., primary, Adams, Diane K., primary, He, Jianzhong, primary, Kalhor, Neda, primary, Zhang, Ming, primary, Xu, Ting, primary, Gao, Hui, primary, Reuben, James M., primary, Qiao, Yawei, primary, Komaki, Ritsuko, primary, Liao, Zhongxing, primary, Edelman, Martin J., primary, Tang, Cha-Mei, primary, and Lin, Steven H., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data File and Legend from Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets

Author

Van Laere, Steven J., primary, Ueno, Naoto T., primary, Finetti, Pascal, primary, Vermeulen, Peter, primary, Lucci, Anthony, primary, Robertson, Fredika M., primary, Marsan, Melike, primary, Iwamoto, Takayuki, primary, Krishnamurthy, Savitri, primary, Masuda, Hiroko, primary, van Dam, Peter, primary, Woodward, Wendy A., primary, Viens, Patrice, primary, Cristofanilli, Massimo, primary, Birnbaum, Daniel, primary, Dirix, Luc, primary, Reuben, James M., primary, and Bertucci, François, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figures from Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets

Author

Van Laere, Steven J., primary, Ueno, Naoto T., primary, Finetti, Pascal, primary, Vermeulen, Peter, primary, Lucci, Anthony, primary, Robertson, Fredika M., primary, Marsan, Melike, primary, Iwamoto, Takayuki, primary, Krishnamurthy, Savitri, primary, Masuda, Hiroko, primary, van Dam, Peter, primary, Woodward, Wendy A., primary, Viens, Patrice, primary, Cristofanilli, Massimo, primary, Birnbaum, Daniel, primary, Dirix, Luc, primary, Reuben, James M., primary, and Bertucci, François, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figures 1,2,3,4,5 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Author

Vitale, Candida, primary, Falchi, Lorenzo, primary, ten Hacken, Elisa, primary, Gao, Hui, primary, Shaim, Hila, primary, Van Roosbroeck, Katrien, primary, Calin, George, primary, O'Brien, Susan, primary, Faderl, Stefan, primary, Wang, Xuemei, primary, Wierda, William G., primary, Rezvani, Katayoun, primary, Reuben, James M., primary, Burger, Jan A., primary, Keating, Michael J., primary, and Ferrajoli, Alessandra, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 2 from TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

Author

Wang, Xiaoping, primary, Saso, Hitomi, primary, Iwamoto, Takayuki, primary, Xia, Weiya, primary, Gong, Yun, primary, Pusztai, Lajos, primary, Woodward, Wendy A., primary, Reuben, James M., primary, Warner, Steven L., primary, Bearss, David J., primary, Hortobagyi, Gabriel N., primary, Hung, Mien-Chie, primary, and Ueno, Naoto T., primary

Published
2023
Full Text
View/download PDF

44. Data from TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

Author

Wang, Xiaoping, primary, Saso, Hitomi, primary, Iwamoto, Takayuki, primary, Xia, Weiya, primary, Gong, Yun, primary, Pusztai, Lajos, primary, Woodward, Wendy A., primary, Reuben, James M., primary, Warner, Steven L., primary, Bearss, David J., primary, Hortobagyi, Gabriel N., primary, Hung, Mien-Chie, primary, and Ueno, Naoto T., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figures from TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

Author

Wang, Xiaoping, primary, Saso, Hitomi, primary, Iwamoto, Takayuki, primary, Xia, Weiya, primary, Gong, Yun, primary, Pusztai, Lajos, primary, Woodward, Wendy A., primary, Reuben, James M., primary, Warner, Steven L., primary, Bearss, David J., primary, Hortobagyi, Gabriel N., primary, Hung, Mien-Chie, primary, and Ueno, Naoto T., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 1 from TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

Author

Wang, Xiaoping, primary, Saso, Hitomi, primary, Iwamoto, Takayuki, primary, Xia, Weiya, primary, Gong, Yun, primary, Pusztai, Lajos, primary, Woodward, Wendy A., primary, Reuben, James M., primary, Warner, Steven L., primary, Bearss, David J., primary, Hortobagyi, Gabriel N., primary, Hung, Mien-Chie, primary, and Ueno, Naoto T., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Materials and Methods from TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

Author

Wang, Xiaoping, primary, Saso, Hitomi, primary, Iwamoto, Takayuki, primary, Xia, Weiya, primary, Gong, Yun, primary, Pusztai, Lajos, primary, Woodward, Wendy A., primary, Reuben, James M., primary, Warner, Steven L., primary, Bearss, David J., primary, Hortobagyi, Gabriel N., primary, Hung, Mien-Chie, primary, and Ueno, Naoto T., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legends from TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

Author

Wang, Xiaoping, primary, Saso, Hitomi, primary, Iwamoto, Takayuki, primary, Xia, Weiya, primary, Gong, Yun, primary, Pusztai, Lajos, primary, Woodward, Wendy A., primary, Reuben, James M., primary, Warner, Steven L., primary, Bearss, David J., primary, Hortobagyi, Gabriel N., primary, Hung, Mien-Chie, primary, and Ueno, Naoto T., primary

Published
2023
Full Text
View/download PDF

49. Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients

Author

Cohen, Evan N., primary, Jayachandran, Gitanjali, additional, Gao, Hui, additional, Peabody, Phillip, additional, McBride, Heather B., additional, Alvarez, Franklin D., additional, Kai, Megumi, additional, Song, Juhee, additional, Shen, Yu, additional, Willey, Jie S., additional, Lim, Bora, additional, Valero, Vicente, additional, Ueno, Naoto T., additional, and Reuben, James M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results